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Whilst poor response to clopidogrel is associated with adverse outcomes uncertainty exists as to how (a) response should be
assessed and (b) poor responders managed. We utilised VerifyNow P2Y12 and short Thrombelastography (TEG) to assess 900mg
doses in (i) initial poor responders to 600mg and (ii) in a randomised comparison with 600mg. Blood was taken before and
six hours post clopidogrel in (i) 30 volunteers receiving 600mg (poor responders received 900mg > t w ow e e k sl a t e r )a n d( i i )
60 patients randomized 1 : 1 to 600mg or 900mg doses. Poor response was deﬁned as TEG %Clotting Inhibition (%CIn) or
VerifyNow Platelet Response Unit (PRU) reduction <30%. (i) Poor responders to 600mg had greater PRU reduction (45.0 versus
20.1%, P = 0.03) and greater %CIn (22.9 versus −15.1%, P = 0.01) after 900mg but (ii) there were no signiﬁcant diﬀerences
between the patient groups. Near-patient assessment of response to clopidogrel is feasible and clinically useful. Whilst ineﬀective
on a population basis 900mg doses increase the eﬀect of clopidogrel in initial poor responders.
1.Introduction
The clinical value of dual antiplatelet therapy with aspirin
and clopidogrel to reduce platelet-mediated cardiovascular
eventsisnowwellestablishedinpatientswithacutecoronary
syndromes and those receiving intracoronary stents. In the
ﬁeld of PCI, in particular, a large and expanding body of
evidence indicates that periprocedural complication rates
can be reduced by loading doses of clopidogrel given at least
6 hours before planned stenting. The superiority of 600mg
loading doses of clopidogrel over 300mg is now widely
accepted [1–4]. There remain several areas of uncertainty
in relation to optimal clopidogrel therapy in PCI patients,
however. First, whether the risk of periprocedural and 30 day
events could be further reduced by a 900mg loading dose.
The current data are discrepant in this regard [5–7]. Second,
it is clear that there is heterogeneity in the response of
individual patients to clopidogrel and that poor responders
are susceptible to both early events [8–10] and later stent
thrombosis [11–14]. Taking these factors into account, there
isalogicalcasetobemadethatallpatientsbeingtreatedwith
clopidogrel should have their platelet function assessed to
ensure a therapeutic response with the intention of reducing
their risk. This concept is undermined by the limitations
of current options for platelet function testing. Tests that
are considered to be the “gold standard” for assessment of
platelet function are generally laboratory based and analyse
the platelet in isolation, rather that providing the clinician
with an impression of the eﬀect of clopidogrel on the
patient’s tendency to clot. The high proportion of patients
labeled as “poor responders” by these assays illustrates their
limited value in the clinical arena. By contrast, clinically
relevant near patient tests are few and there is uncertainty
about their reliability. As a result global testing of patient
responses to clopidogrel still does not occur, despite the
knowledge that if it did it has the potential to reduce the
incidence of both periprocedural myocardial infarction and
stent thrombosis.2 Thrombosis
In this study we have the following aims:
(1) to investigate the incidence of poor response to
clopidogrel600mginhealthyvolunteersandtoassess
whether the response of these individuals could be
modiﬁed by 900mg loading;
(2) to compare platelet function in patients being con-
sidered for elective PCI and randomised to either a
600mg or 900mg loading dose of clopidogrel.
These experiments employed two near patient tests
of platelet function: (a) VerifyNow and (b) a previously
described and validated modiﬁcation of Thrombelastograph
PlateletMapping [15]. The latter, “short TEG” provides an
assessmentofplateletfunctioninwholebloodin15minutes.
The overall hypothesis for these experiments was that
near patient assessment of platelet function in individual
patients is feasible and provides clinically valuable informa-
tion that could be used to tailor clopidogrel therapy where
response was deemed to be inadequate.
2. Methods
2.1. Study Population. Approval was obtained from the
Southampton and South West Hampshire Research Ethics
committee B prior to commencing the study. All subjects
provided written informed consent.
2.2. Group A. 30 volunteers were recruited and received a
600mg loading dose of clopidogrel. Poor responders to this
initial loading dose received a 900mg loading dose of clopi-
dogrel at least two weeks later. Individuals were excluded if
they had taken antiplatelet medication or nonsteroidal anti-
inﬂammatory medication within 14 days or if they had a
history of peptic ulceration, bronchial asthma, or bleeding.
2.3.GroupB. 60patientsreceivingaloadingdoseofclopido-
grelpriortoeitherelectivePCIorcoronaryangiographywith
aviewtoproceedwererecruited.Theywererandomised1 : 1
to600mgor900mgloadingdosesofclopidogrel.Allpatients
were established on aspirin 75mg maintenance therapy for
>28 days. Exclusion criteria were use of antiplatelet or
anticoagulantmedicationotherthanaspirininthepreceding
28 days, known intolerance to clopidogrel, planned use
of glycoprotein IIb/IIIa inhibitor, recent bleeding, major
haematological disturbance, and known malignancy.
2.4. Sample Analysis. Blood tests were taken for Thrombe-
lastograph PlateletMapping (Haemoscope Corp, Ill, USA)
(TEG) and VerifyNow P2Y12 assays (Accumetrics Inc.,
CA, USA) immediately before and six hours after drug
administration in Group A and prior to and one, two,
six and 20–24 hours after drug administration (before
administration of maintenance doses of clopidogrel) in
Group B. In all subjects venesection was performed from
the antecubital fossa and the ﬁrst 2mL of blood discarded.
Blood was then drawn into 2mL 3.2% sodium citrate
Vacutainers for VerifyNow analysis and a 6mL Lithium
Heparin Vacutainer for TEG analysis. Samples were analysed
according to manufacturer’s instructions. The percentage
reduction in VerifyNow PRU from baseline was calculated
at each timepoint, with reduction of <30% considered
to represent poor response to clopidogrel. TEG analysis
was performed using TEG PlateletMapping (Haemoscope,
Ill, USA) which incorporates three channels: a “thrombin
channel” with maximal platelet activation achieved through
reversal of heparin with heparinase and maximal throm-
bin stimulation with kaolin activation; a “ﬁbrin channel”
representing platelet independent clot formation (generated
without thrombin generation by the addition of reptilase
and factor XIIIa to a heparinised sample) and channels
with reptilase, factor XIIIa and ADP stimulation “the ADP
channel.”
For TEG samples the percentage platelet inhibition
(%PIn) and percentage clotting inhibition (%CIn) were
calculated as previously described with %PIn and %CIn of
<30% considered to represent poor response [15, 16].
Brieﬂy, the %PIn was calculated from the maximum
amplitude of the TEG traces by comparing the ADP channel
with maximal platelet activation in the thrombin channel
whilstsubtractingtheeﬀectoftheﬁbrinchannel[16]andthe
%CIn was calculated from the area under curve of the TEG
trace by comparing the response to ADP with the response
to thrombin [14].
In Group B analysis of results was performed by an
individual blinded to the dose administered.
Some patients received unplanned use of glycoprotein
IIb/IIIainhibitors(allAbciximab)orBivalirudinduringPCI.
In these cases blood tests were not performed at any time
after administration of Abciximab or within six hours of
cessation of Bivalirudin infusion.
2.5. Clinical Endpoints. F o rG r o u pBr a t e so fm a j o ra n d
minor bleeding, periprocedural myocardial infarction, stent
thrombosis, and death were compared between the two
groups.
2.6. Statistical Analysis. For Group A previous data suggest
that a group size of 30 is required to identify 10 poor
responders [15, 17]. Ten poor responders would be required
to detect a 10% diﬀerence in platelet function with the
higher dose with 80% power using paired, two-tailed t-tests.
For Group B the study has been powered to detect a 25%
relative diﬀerence in platelet inhibition with 80% power.
Signiﬁcance between the groups was determined using two-
tailed, two group t-tests with a P value of <.05 considered to
representsigniﬁcance.Dataarepresentedasthemean ±95%
conﬁdenceintervalofthemean.Fisher’sexacttestswereused
to determine diﬀerences between numbers of responders.
3. Results
3.1. Group A
3.1.1. Baseline Demographics. 15 males and 15 females were
recruited. Age 33 ± 4 years. Two volunteers were smokers.Thrombosis 3
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Figure 1: Change in PRU and %CIn 6 hours after clopidogrel
therapy for (i) all volunteers taking 600mg clopidogrel (ii) poor
responders taking 600mg clopidogrel (iii) poor responders taking
900mg clopidogrel.
Two individuals were withdrawn prior to study completion
astheydevelopedaprespeciﬁedexclusioncriteria.Datafrom
28 volunteers was therefore analysed.
3.1.2. Antiplatelet Eﬀect
VerifyNow. Baseline mean PRU was 264 ± 16 compared to
106 ±28sixhoursaftera600mgloadingdoseofclopidogrel.
Mean % reduction in PRU was 59.9 ± 10.1%.
Five volunteers (17%) were classiﬁed as nonresponders
by VerifyNow. Initial nonresponders had signiﬁcantly greater
reduction in PRU after a 900mg loading dose of clopidogrel
(45.0 versus 20.1%, P = .03). Four of the ﬁve (80%)
nonresponderstoa600mgdosewereclassiﬁedasresponders
after the 900mg dose (Figure 1, Table 1).
Thrombelastography. Six hours after the initial 600mg load-
ingdoseofclopidogrel%PInwas48.1 ±11.6,%CInwas37.7
± 15.9%. Nine volunteers (31%) were classiﬁed as nonre-
sponders by both %PIn and %CIn. In nonresponders to the
600mg dose %PIn (32.0 versus 9.9%, P = .01) and %CIn
(22.9 versus −15.1%, P = .01) were signiﬁcantly greater after
900mg of clopidogrel. Of the nine nonresponders to 600mg
clopidogrel four (44%) were classiﬁed as responders after
a 900mg loading dose by both %PIn and %CIn (Figure 1,
Table 1).
3.2. Group B
3.2.1. Baseline Demographics. There were no signiﬁcant
diﬀerences between the 2 groups in terms of baseline
demographics, haematological parameters or in procedure
undertaken (Table 2). Four patients received Abciximab, one
patient received Bivalirudin and 18 patients were discharged
prior to the 20–24 hour timepoint. Data was therefore
analysed from 87% of the planned datapoints (100% at
baseline, one and two hours, 92% at the six hour timepoint
and 70% at the 20–24 hour timepoint).
3.2.2. Clinical Endpoints. There were no signiﬁcant diﬀer-
ences between the groups in terms of procedural compli-
c a t i o n s .T h e r ew e r en om a j o rb l e e d sa n dn oa c u t es t e n t
thromboses. There was one access site haematoma (in the
900mg group). There was no diﬀerence in periprocedural
myocardial infarction (17% in the 600mg group and 20%
in the 900mg group).
3.2.3. Antiplatelet Eﬀect
VerifyNow. Whilst there was no diﬀerence in % reduction
in PRU between the two groups at the one and two hour
timepoints, there was a trend towards greater reduction at
six hours (55.3 ± 9.1v e r s u s3 7 .2 ± 15.8, P = .06) and
signiﬁcantlygreaterreductionby24hours(60.9 ± 9.1v ersus
37.9 ±17.0, P = .04) in the 900mg group (Table 3).
There were signiﬁcantly fewer poor responders in the
900mg group at the six hour timepoint (Table 4).
Thrombelastography. Whilst the %PIn and %CIn were
greater in the 900mg group at all timepoints there were no
signiﬁcant diﬀerences between the two groups. There was a
trend towards greater %PIn in the 900mg group at six hours
(45.9 ± 8.4v e r s u s3 3 .2 ± 8.9, P = .06) and at 24 hours
(37.8 ± 7.7v e r s u s2 4 .7 ± 7.1, P = .06) (Table 3). There were
nodiﬀerencesbetweenthetwogroupsinthenumberofpoor
responders at any timepoint (Table 4).
4. Discussion
There is increasing evidence that poor response to clopido-
grel post PCI correlates with subsequent ischaemic events
and even death [3, 4, 8–10, 18]. Furthermore, studies have
speciﬁcally suggested that relative hyporesponsiveness to
clopidogrel increases the risk of Stent thrombosis [11–14].
However, at present responses are not routinely monitored.
This is largely due to (a) the expense and complexity of
laboratory based assays of platelet function; (b) diﬃculties
in determining the threshold for poor response with poor
positive predictive values; (c) uncertainty in how to manage
poor response.
There is now evidence that repeated loading doses [19];
increased maintenance doses of clopidogrel [19, 20]; and
changing to Ticlopidine [19]o rP r a s u g r e l[ 21] improve the
observed antiplatelet response and can decrease the rate of
poor responders to clopidogrel by 60 [20] to 78.9% [19]
but as yet little direct evidence that these strategies improve
clinical outcomes post PCI. However, recently Bonello et al.,
using a strategy of VASP guided clopidogrel loading prior to
PCI with up to 3 further 600mg clopidogrel loading doses
administered to obtain adequate response did, in addition
to improving response to clopidogrel, achieve signiﬁcantly4 Thrombosis
Table 1: The %PIn, %CIn, and % Change in PRU of (a) all healthy volunteers 6 hours post 600mg clopidogrel, (b) poor responders to
600mg: 6 hours post 600mg clopidogrel, (c) poor responders to 600mg: 6 hours post 900mg clopidogrel. Data presented as mean ± 95%
conﬁdence interval of the mean (numbers analysed).
All Volunteers Initial Poor Responders (to 600mg)
Response to 600mg Response to 900mg P
%PIn 48.1 ±11.6 (28) 9.9 ±9 (9) 32.2 ±16.3( 9 ) . 0 1
%CIn 37.7 ±15.9 (28) −15.1 ±21.6 (9) 22.9 ±15.9( 9 ) . 0 1
% Change in PRU 59.9 ±10.1 (28) 20.1 ±8.2 (5) 45.0 ±16.3( 5 ) . 0 3
Table 2: Baseline demographics and haematological parameters in
PCI patients randomized to 600mg and 900mg clopidogrel loading
doses.
600mg group 900mg group P value
Age 65 ± 3.8 65.2 ± 3.7 .92
% male 70% 63.30% .78
Weight 81.8 ± 5.6 81.3 ± 5.5 .86
Aspirin dose 80.4 ± 11.3 81.3 ± 11.4 .88
PCI performed 16 (53%) 19 (63%) 1.00
No sig. coronary disease 4 (13%) 1 (3%) .35
Smokers 6 (20%) 1 (3%) .10
Diabetics 6 (20%) 2 (7%) .25
Haematoma 0 1 (3%) 1.00
Enzyme rise 5 (17%) 6 (20%) .72
Hb 140 ± 5.7 139 ± 5.7 .86
Plt count 235 ± 23.7 240 ± 23.7 .68
Haematocrit 0.41 ± 0.01 0.41 ± 0.01 .84
e GFR 70.4 ± 5.4 70 ± 5.3 .88
INR 0.99 ± 0.0 0.99 ± 0.0 .94
Table 3: Response to clopidogrel in PCI patients randomised to
600mg and 900mg loading doses. (PRU: reduction compared to
baseline; %PIn: Percentage platelet inhibition due to clopidogrel;
%CIn: Percentage clotting inhibition due to clopidogrel.)
600mg group 900mg group P value
PRU
1h o u r 1 0 .4 ±10.32 2 .3 ±9.1. 0 9
2h o u r 3 5 .9 ±13.34 4 .5 ±9.5. 3 1
6h o u r 3 7 .2 ±15.85 5 .3 ±9.1. 0 6
24 hour 37.9 ±17.06 0 .9 ±9.1. 0 4
%PIn
1 hour 13.0 ± 7.2 22.0 ± 7.6 .10
2 hours 26.5 ± 9.5 33.2 ± 8.5 .31
6 hours 33.2 ± 8.9 45.9 ± 8.4 .06
24 hours 24.7 ± 7.1 37.8 ± 7.7 .06
%CIn
1 hour 4.0 ± 11.2 4.4 ± 12.4 .95
2 hours 19.8 ± 11.7 23.3 ± 12.1 .68
6 hours 25.8 ± 8.6 35.7 ± 8.7 .13
24 hours 18.1 ± 11.5 31.2 ± 10.2 .19
Table 4: The percentage of “poor responders” to clopidogrel
in PCI patients randomized to 600mg and 900mg clopidogrel
loading doses. Poor response is deﬁned as: PRU: <30% reduction
in Accumetrics PRU from baseline; %PIn: short TEG %PIn <30%;
%CIn: short TEG %CIn <30%.
600mg group 900mg group P value
PRU
1 hour 77 (23/30) 67 (20/30) .57
2 hour 40 (12/30) 27 (8/30) .29
6 hour 41 (11/27) 12 (3/26) .02
24 hour 41 (7/17) 15 (3/20) .07
%PIn
1 hour 70 (21/30) 77 (23/30) .77
2 hours 60 (18/30) 43 (13/30) .44
6 hours 43 (12/28) 30 (10/28) .40
24 hours 61 (11/18) 37 (7/19) .51
%CIn
1 hour 77 (23/30) 80 (24/30) .77
2 hours 43 (13/30) 53 (16/30) .45
6 hours 36 (10/28) 33 (9/27) 1.00
24 hours 37 (7/19) 55 (11/20) .34
improved MACE rates at 30 days without increased bleeding
[22].
However, 900mg loading doses of clopidogrel could
increase both the speed and extent of the antiplatelet
eﬀect and decrease the number of poor responders but
previousstudieshaveshowndiscrepantresults.TheALBION
study suggested an increased eﬀect with 900mg doses [5].
However ISAR-CHOICE found no diﬀerences in eﬀect
and no diﬀerences in levels of the active metabolite of
clopidogrel suggesting that absorption or metabolism of
clopidogrel may be a limiting factor [6]. Price et al. also
showed no diﬀerence in the magnitude of response or the
time to maximal response with VerifyNow P2Y12 assays
[7].
We have compared the antiplatelet eﬀects of 600mg and
900mg loading doses of clopidogrel using VerifyNow and
TEG, two rapid reliable tests of response to clopidogrel and
platelet reactivity whilst on clopidogrel that are suitable for
nearpatientclinicaluse.Bothtestshavebeenshowntocorre-
late with optical aggregation, the current “gold standard” for
measuring platelet activity [16, 23, 24]. In addition we have
shown that both assays identify poor response to clopidogrelThrombosis 5
in patients with previous stent thrombosis [14]. Using these
techniques we have demonstrated that near patient testing
is feasible and provides individual patient data on response
to clopidogrel in a time dependent manner. Further, these
tests can both detect poor responders and also reassess
responses after increased dose to determine if the response
has become adequate. These data also demonstrate that
whilst 900mg clopidogrel loading doses do not signiﬁcantly
enhance platelet inhibition compared to 600mg doses in the
general patient population, selective and individualised dose
adjustmentinpoorrespondersimprovesthelevelofresponse
and reduces the number of poor responders.
This study has some limitations. We did not correlate
the results of our two near patient assays with laboratory
basedassays.Inemergenciessuchasprimaryangioplastythis
strategy would also be inappropriate and the role of “top
up” doses in this context should be explored. In addition,
this study was not designed to investigate long term clinical
outcomes.
If these techniques and this approach of individualized
therapy is to be incorporated into routine clinical practice
large clinical outcome trials are obviously required. We do
believe that in order to maximize the chances of these
techniques becoming widespread these trials should be
performed using rapid, simple near patient assays.
5. Conclusions
We have shown that near patient assessment of response to
antiplatelet therapy with both VerifyNow and short TEG is
feasibleandcouldbeusedtotailorclopidogreltherapywhere
responses are deemed to be inadequate. Whilst there remain
contentious issues, particularly in determining the threshold
for “poor response” we believe that there is a clear role for
universal near patient assessment of response to antiplatelet
therapy and that soon it may become unethical to manage
high risk individuals without it.
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